Biospectal SA, a remote patient monitoring and biosensing software company, closed a $4.3 million seed funding round led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021. Read more.
Related Posts
Surgery AI Startup Apella Technology Raises $21M
San Francisco-based Apella collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information.
December 20, 2021
Brave Health Raises $10M in Series B
City Light Capital, Union Square Ventures, and Able Partners led the round.
October 26, 2021
CMS Pumping $25M more into HCBS Money Follows the Person Program
The funds will be going to new states and territories, increasing the total number of states and territories participating in MFP to 41.
August 23, 2022